With two nonequivalent vaccines available and different recommendations for different patient populations, vaccination against Streptococcus pneumoniae can be confusing. Here we try to clarify the situation.
S
treptococcus pneumoniae (the "pneumococcus") causes a variety of clinical syndromes that range from otitis media to bacteremia, meningitis, and pneumonia. Hardest hit are immunocompromised people and those at the extremes of age. Therefore, preventing disease through pneumococcal vaccination is very important in these groups.
This review summarizes the current guidelines from the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) for pneumococcal immunization in adults.
■ STRIKES THE VERY YOUNG, VERY OLD, AND IMMUNOCOMPROMISED
Invasive pneumococcal disease is defi ned as infection in which S pneumoniae can be found in a normally sterile site such as the cerebrospinal fl uid or blood, and it includes bacteremic pneumonia. 1 By far the most common type of pneumococcal disease is pneumonia, followed by bacteremia and meningitis (Figure 1 ) 2, 3 ; about 25% of patients with pneumococcal pneumonia also have bacteremia. 2 Invasive pneumococcal disease most often occurs in children age 2 and younger, adults age 65 and older, and people who are immunocompromised. In 2010, the incidence was 3.8 per 100,000 in people ages 18 to 34 but was 10 times higher in the elderly and those with compromised immunity. 1 Even now that vaccines are available, invasive pneumococcal disease continues to cause 4,000 deaths per year in the United States. A: Chronic obstructive pulmonary disease falls into the at-risk category for patients ages 19 to 64 with comorbidities. This patient is a candidate for PPSV23. The ACIP guidelines are silent on the additional need for PCV13 for multiple short courses of corticosteroids.
Vaccination schedules can be found at www. cdc.gov/vaccines/schedules/. Questions can be posted at www.cdc.gov/cdc-info/.
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an outer capsule composed of polysaccharides that protect the bacterium from being ingested and killed by host phagocytic cells. Some 91 serotypes of this organism have been identifi ed on the basis of genetic differences in capsular polysaccharide composition.
Currently, two inactivated vaccines are available that elicit antibody responses to the most common pneumococcal serotypes that infect humans.
• PPSV23 (pneumococcal polysaccharide vaccine-23, or Pneumovax 23) contains purifi ed capsular polysaccharides from 23 pneumococcal serotypes.
• PCV13 (pneumococcal conjugate vaccine-13, or Prevnar 13) contains purifi ed capsular polysaccharides from 13 serotypes that are covalently bound to (conjugated with) a carrier protein.
■ PPSV23 AND PCV13 ARE NOT THE SAME
Apart from the number of serotypes covered, the two vaccines differ in important ways. Both of them elicit a B-cell-mediated immune response, but only PCV13 produces a T-celldependent response, which is essential for maturation of the B-cell response and development of immune memory. PPSV23 generally provides 3 to 5 years of immunity, and repeat doses do not offer additive or "boosted" protection. It is ineffective in children under 2 years of age.
Pneumococcal conjugate vaccine has been available since 2000 for children starting at 2 months of age. Since then it has directly reduced the incidence of invasive pneumococcal disease in children and indirectly in adults. The impact on pneumococcal disease rates in adults has probably been related to reduction in rates of pneumococcal nasopharyngeal carriage in children, another unique benefi t of conjugated vaccines. 3 In December 2011, the US Food and Drug Administration (FDA) approved PCV13 for adults on the basis of immunologic studies and anticipation that clinical effi cacy would be similar to that observed in children.
■ HOW EFFECTIVE ARE THEY?
The effi cacy and safety of PPSV23 and PCV13 have been studied in a variety of patient populations. Though antibody responses to PCV13 were similar to or better than those with PPSV23, no studies of specifi c correlations between immunologic responses and disease outcomes are available. 4, 5 In large studies in healthy adults, both vaccines reduced the incidence of invasive pneumococcal disease. A study in more than 47,000 adults age 65 and older showed a signifi cant reduction in pneumococcal bacteremia (hazard ratio 0.56, 95% confi dence interval 0.33-0.93) in those who received PPSV23 compared with those who received placebo. 6 However, PPSV23 was not effective in preventing nonbacteremic and noninvasive pneumococcal community-acquired pneumonia when all bacterial serotypes were considered. 6 In a placebo-controlled trial in more than 84,000 people age 65 and older, PCV13 prevented both nonbacteremic and bacteremic community-acquired pneumococcal pneumonia due to serotypes included in the vaccine (relative risk reduction 45%, P < .007) and overall invasive pneumococcal disease due to serotypes included in the vaccine (relative risk reduction 70%, P < .001). 7 Both vaccines have also demonstrated effi cacy in immunocompromised adults. Several studies showed an equivalent or superior antibody response to a seven-valent pneumococcal conjugate vaccine (PCV7, which has been replaced by PCV13) compared with PPSV23 in adults with human immunodefi ciency virus (HIV) infection. 8, 9 While specifi c clinical studies of the effi cacy of PCV13 among immunocompromised people are not available, a study of vaccination with PCV7 in 496 people in Malawi, of whom 88% were infected with HIV, found that the vaccine was effective in preventing invasive pneumococcal disease (hazard ratio 26%, 95% confi dence interval 0.10-0.70).
■ AT-RISK PATIENT POPULATIONS
Since both PPSV23 and PCV13 are approved for use in adults, it is important to understand appropriate indications for their use. The ACIP recommends pneumococcal vaccination in adults at an increased risk of invasive pneumococcal disease: ie, people age 65 and older, at-risk people ages 19 to 64, and people who are immunocompromised or asplenic. A more robust antibody response has been shown with PCV13 compared to PPSV23 in healthy people. 5 Of note, when PPSV23 is given before PCV13, there is a diminished immune response to PCV13. 11, 12 Therefore, unvaccinated people who will receive both PCV13 and PPSV23 should be given the conjugate vaccine PCV13 fi rst. (See Commonly asked questions on page 428.)
■ ADULTS AGE 65 AND OLDER: ONE DOSE EACH OF PCV13 AND PPSV23
Before September 2014, the ACIP recommended one dose of PPSV23 for adults age 65 and older to prevent invasive pneumococcal disease. 13 With evidence that PCV13 also produces an antibody response and is clinically effective against pneumococcal pneumonia in older people, the ACIP now recommends that all adults age 65 and older receive one dose of PCV13 and one dose of PPSV23. 3, 14 Based on antibody studies, the ACIP recommends giving PCV13 fi rst and PPSV23 12 months after. 11, 12 Patients who received PPSV23 at age 65 or older should receive PCV13 at least 1 year after PPSV23 (Figure  2) . 3, 14 Patients who had previously received one dose of PPSV23 before age 65 who are now age 65 or older should receive one dose of PCV13 at least 1 year after PPSV23 and an additional dose of PPSV23 at least 5 years after the fi rst dose of PPSV23 and at least 1 year after the dose of PCV13. 3 Patients who received a dose of PCV13 before age 65 do not need an additional dose after age 65.
The Centers for Medicare and Medicaid Services have updated the reimbursement for pneumococcal vaccines to include both PCV13 and PPSV23. Patients can receive one dose of pneumococcal vaccine followed by a different, second pneumococcal vaccine at least 11 full months after the month in which the fi rst pneumococcal vaccine was administered.
■ AT-RISK PATIENTS AGES 19 TO 64
Before 2012, the ACIP recommended that patients at risk, including immunocompromised patients and those without a spleen, with cerebrospinal fl uid leaks, or with cochlear implants, receive only PPSV23 before age 65. 13 In 2010, 50% of cases of invasive pneumococcal disease in immunocompromised adults were due to serotypes contained in PCV13. 16 Additionally, according to CDC data from 2013, in adults ages 19 to 64 at risk of pneumococcal disease, only 21.2% had received pneumococcal vaccine. 17 With information on epidemiology, safety, and effi cacy, as well as expanded FDA approval of PCV13 for adults in 2011, the ACIP updated its guidelines for pneumococcal immunization of adults with immunocompromising conditions in October 2012. 16 The updated guidelines now include giving PCV13 to adults at increased risk of invasive pneumococcal disease. 16 Adults under age 65 at risk of invasive pneumococcal disease can be further divided into those who are immunocompetent with comor- PALLOTTA AND REHM bid conditions, and those with cochlear implants or cerebrospinal fl uid leak. (Table 1) . 16 Patients with cochlear implants or cerebrospinal fl uid leaks should receive one dose of PCV13 followed by one dose of PPSV23 8 weeks later. If PPSV23 is given fi rst in this group, PCV13 can be given 1 year later.
Immunocompetent patients with comorbid conditions, including cigarette smoking, chronic heart, liver, or lung disease, asthma, cirrhosis, and diabetes mellitus, should receive one dose of PPSV23 before age 65 ( Table 1) . 16 
■ IMMUNOCOMPROMISED AND ASPLENIC PATIENTS
Immunocompromised patients at risk for invasive pneumococcal disease include patients with functional or anatomic asplenia or immunocompromising conditions such as HIV infection, chronic renal failure, generalized malignancy, solid organ transplant, iatrogenic immunosuppression (eg, due to corticosteroid therapy), and other immunocompromising conditions. 16 Patients on corticosteroid therapy are considered immunosuppressed if they take 20 mg or more of prednisone daily (or an equivalent corticosteroid dose) for at least 14 days. 16 These immunocompromised patients should receive one dose of PCV13, followed by a PPSV23 dose 8 weeks later and a second PPSV23 dose 5 years after the fi rst. 16 The time between vaccinations is also important. If PCV13 is given fi rst, PPSV23 can be given after at least 8 weeks. If PPSV23 is given fi rst, PCV13 should be given after 12 18 Challenges include the cost of vaccine coverage, limited time (with competing priorities during offi ce appointments or hospitalizations), patient refusal, and knowledge gaps.
Strategies to overcome barriers include incorporating vaccination into protocols and procedures; educating healthcare providers and patients about pneumococcal disease, vaccines, costs, and reimbursement; engaging nonclinical staff members; and monitoring local vaccination rates. However, the most important factor affecting whether adults are vaccinated is whether the healthcare provider recommends it.
■ AN OPPORTUNITY TO IMPROVE
In the last 30 years, great strides have been made in recognizing and preventing pneumococcal disease, but challenges remain. Adherence to the new ACIP guidelines for pneumococcal vaccination in immunocompromised, at risk and elderly patients is important in reducing invasive pneumococcal disease.
Healthcare providers have the opportunity to improve pneumococcal vaccination rates at outpatient appointments to decrease the burden of invasive pneumococcal disease in at-risk populations. A comprehensive understanding of the guideline recommendations for pneumococcal vaccination can aid the provider in identifying patients who are eligible for vaccination.
Adult pneumococcal immunization rates are low due to missed opportunities. Healthcare providers can improve these rates by viewing every patient encounter as a chance to provide vaccination. Information from reference 16.
